StockNews.AI
PALI
StockNews.AI
202 days

Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress

1. Palisade Bio's abstract accepted for Crohn's & Colitis Congress presentation. 2. Presentation on PALI-2108’s efficacy in reducing ulcerative colitis symptoms. 3. The event takes place from February 6-8, 2025 in San Francisco.

3m saved
Insight
Article

FAQ

Why Bullish?

Presentation at a major congress can generate positive investor interest, much like past events for biotech firms which often trigger stock price increases.

How important is it?

The presentation can highlight PALI's developments and attract investor attention, making it important for stock movements.

Why Short Term?

The upcoming presentation may provide immediate market reactions based on investor perception.

Related Companies

PALI
Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that its abstract has been accepted for poster presentation at the Crohn’s & Colitis Congress being held February 6-8, 2025 in San Francisco, CA. Details of the poster presentation are as follows: Session: Poster and Exhibition Hall ReceptionPoster Title: PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug is Activated in the Colon and Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model Session Dates and Times: February 7, 2025 from 5:00 PM to 6:30 PM PSTPresentation Location: Level 1 – Exhibition Hall – Moscone West For more information about the congress, please visit crohnscolitiscongress.org. About Palisade Bio  Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com. Investor Relations ContactJTC Team, LLCJenene Thomas 908-824-0775PALI@jtcir.com

Related News